^
No biomarker
Rhabdomyosarcoma
dactinomycin
Sensitive: A1 - Approval
No biomarker
Rhabdomyosarcoma
IE
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
VAC
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride + cyclophosphamide oral + etoposide IV + vincristine
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
trabectedin
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
ADX-2191
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
vinorelbine
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
topotecan
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
irinotecan
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
SA033
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
temozolomide + irinotecan + vincristine
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
cyclophosphamide oral + vinorelbine tartrate
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
carboplatin + etoposide oral
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
vincristine + dactinomycin
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
irinotecan + vincristine
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride + ifosfamide
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
cyclophosphamide oral + topotecan
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride + ifosfamide + vincristine
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride + ifosfamide + cyclophosphamide oral + vincristine
Sensitive: A2 - Guideline
BRAF-MAD1L1 fusion
Rhabdomyosarcoma
anlotinib
Resistant: C4 – Case Studies
HRAS mutation
Rhabdomyosarcoma
tipifarnib
Sensitive: D – Preclinical
KDM1A overexpression
Rhabdomyosarcoma
SP2577
Sensitive: D – Preclinical
PAX3-FOXO1 fusion
Rhabdomyosarcoma
SNDX-275
Sensitive: D – Preclinical